Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04324021 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
A Phase 2 study, sponsored by Swedish Orphan Biovitrum.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04324021 is a Phase 2 study that was terminated before completion, run by Swedish Orphan Biovitrum. The registered enrollment target is 16 participants.
The verdict
NCT04324021, a Phase 2 study, was terminated before completion, sponsored by Swedish Orphan Biovitrum.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the most important negative prognostic factors in patients infected with sSARS-CoV-2. The objective of this study is to investigate new treatment options to reduce the number of patients requiring mechanical ventilation. This is intended to address the most urgent need to preserve the access to intensive care unit support to the lowest possible number of patients and may potentially reduce mortality.
Interventions
- BIOLOGICAL Emapalumab
- BIOLOGICAL Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-04-02 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04324021
The ClinicalTrials.gov registry entry for NCT04324021 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Emapalumab is the first listed.
NCT04324021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04324021 about?
NCT04324021 is a clinical study titled "Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.". Hyper-inflammation, caused by a cytokine storm resulting from an exaggerated response of the immune system in the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is considered to represent one of the most important negative prognostic factors in patients infected with sSARS...
What is the current status of trial NCT04324021?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-04-02. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT04324021?
The interventions under investigation include: Emapalumab (BIOLOGICAL), Anakinra (BIOLOGICAL).
Who is sponsoring clinical trial NCT04324021?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.